|
|
|
|
LEADER |
00000cam a2200000Ia 4500 |
001 |
in00002442893 |
005 |
20211202191440.0 |
006 |
m d f |
007 |
cr an||||||||| |
008 |
090423s2008 mdu s f000 0 eng d |
035 |
|
|
|a (OCoLC)ocn319070753
|
040 |
|
|
|a GPO
|c GPO
|d MvI
|d UtOrBLW
|
049 |
|
|
|a WWW
|
074 |
|
|
|a 0499-T-02 (online)
|
086 |
0 |
|
|a HE 20.4802:IM 7
|
245 |
0 |
0 |
|a Guidance for industry :
|b Q3A impurities in new drug substances.
|
246 |
3 |
0 |
|a Q3A impurities in new drug substances
|
264 |
|
1 |
|a Sliver Spring, MD :
|b U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research ;
|a Rockville, MD :
|b Center for Biologics Evaluation and Research,
|c [2008]
|
300 |
|
|
|a 14 pages :
|b digital, PDF file.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
538 |
|
|
|a Mode of access: Internet at the FDA CBER Web site. Address as of 4/23/09: http://www.fda.gov/cber/gdlns/ichq3a.pdf ; current access is available via PURL.
|
500 |
|
|
|a Title from PDF title page (viewed on Apr. 23, 2009).
|
500 |
|
|
|a "ICH".
|
500 |
|
|
|a "June 2008".
|
500 |
|
|
|a "Revision 2".
|
500 |
|
|
|a Electronic resource.
|
650 |
|
0 |
|a Drug adulteration.
|
650 |
|
0 |
|a Drugs
|x Analysis.
|
650 |
|
0 |
|a Drug approval
|z United States.
|
710 |
2 |
|
|a Center for Drug Evaluation and Research (U.S.)
|
710 |
2 |
|
|a Center for Biologics Evaluation and Research (U.S.)
|
711 |
2 |
|
|a International Conference on Harmonisation.
|
856 |
4 |
0 |
|u https://purl.fdlp.gov/GPO/LPS111818
|t 0
|
999 |
|
|
|a MARS
|
999 |
f |
f |
|s a517c4b0-e9af-3b8c-8cbe-e80d64e63afe
|i 59bff92a-4476-3331-9af0-d403de654bd1
|t 0
|
952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|d Available Online
|t 0
|e HE 20.4802:IM 7
|h Superintendent of Documents classification
|
998 |
f |
f |
|a HE 20.4802:IM 7
|t 0
|l Available Online
|